ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

International Journal of Dermatology

International Journal of Dermatology

Volume 38 Issue 8, Pages 601 - 603

Published Online: 25 Dec 2001

Journal compilation © 2010 International Society of Dermatology



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 149K)  | Related Articles | Citation Tracking

CLINICAL TRIAL
Fluconazole vs. Itraconazole in the treatment of tinea versicolor
Fernando Montero-Gei MD, Miguel Eduardo Robles MD and Patricia Suchil MD
  From the Medical School, San Juan de Dios Hospital, University of Costa Rica, San Jose, Costa Rica, the Instituto Guatemalteco de Seguridad Social, Guatemala City, Guatemala, and the Centro Dermatologico Pascua, Mexico City, Mexico
Correspondence
Fernando Montero-Gei, md
P.O. Box 2157–1000
San Jose
Costa Rica
This study was supported in part by a grant from Pfizer Inc, New York, NY.
Drug names
fluconazole: Diflucan
itraconazole: Sporanox
Copyright 1998 Blackwell Science Ltd

ABSTRACT

Ninety patients with tinea versicolor were randomly assigned to treatment with either a single 450-mg dose of fluconazole, two 300-mg doses of fluconazole given 1 week apart, or itraconazole 200 mg daily for 7 days. At the end of treatment, the cure rate for itraconazole (20%) was significantly higher (P = 0.024) than that for fluconazole 450 mg (0%). When cure plus improvement was considered, response rates among the three treatment groups were comparable (97, 100, and 97% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively). Failure rates at the end of treatment were low (0–3%). Clinical response rates achieved at the end of treatment generally were maintained at 1 month, but tended to decrease at 2 months. Eradication at the end of treatment was not significantly different among the treatment groups (17, 33, and 38% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively). At 1 month, the eradication rate was significantly higher (P = 0.012) for the two-dose than the single-dose fluconazole treatment group (97 and 70%, respectively). At 2 months, reinfection rates were 21, 20, and 4% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively. No clinical adverse events occured, and no patients were withdrawn for laboratory abnormalities.


DIGITAL OBJECT IDENTIFIER (DOI)
10.1046/j.1365-4362.1999.00733.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Sign Up Now
Wiley Medical Twitter